All In Biotech

Drug Trial Radar · NCT07189169

QA108 Phase III Study in Subjects With Intermediate AMD

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of QA108 Granules in the Treatment of Intermediate Age-Related Macular Degeneration (Type of Yang-Hyperactivity Due to Yin-Deficiency)

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jul 8, 2025

Primary completion

Mar 1, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Smilebiotek Zhuhai LimitedIndustry
Sponsor type
Industry
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Conditions

  • Intermediate Age-Related Macular Degeneration

Interventions

  • QA108 granulesDrug

    Take the medication as required for 24 weeks

  • QA108 granules placeboDrug

    Take the medication as required for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in drusen areaTime frame: weeks 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.